Back to Newsroom

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts

SOUTH SAN FRANCISCO, July 17, 2017 – STRO-001, Sutro Biopharma’s antibody drug conjugate targeting the CD74 cell surface protein in hematologic B-cell malignancies, has been shown to eradicate tumors in human xenograft models of non-Hodgkin lymphoma and multiple myeloma – diseases that Sutro plans to evaluate for treatment in a Phase I clinical trial planned for early 2018.
READ MORE…